These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7591480)

  • 1. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).
    Pinski J; Schally AV; Yano T; Groot K; Srkalovic G; Serfozo P; Reissmann T; Bernd M; Deger W; Kutscher B
    Int J Pept Protein Res; 1995 May; 45(5):410-7. PubMed ID: 7591480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.
    Pinski J; Yano T; Janaky T; Nagy A; Juhasz A; Bokser L; Groot K; Schally AV
    Int J Pept Protein Res; 1993 Jan; 41(1):66-73. PubMed ID: 8436447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75).
    Gonzalez-Barcena D; Vadillo Buenfil M; Garcia Procel E; Guerra-Arguero L; Cardenas Cornejo I; Comaru-Schally AM; Schally AV
    Eur J Endocrinol; 1994 Sep; 131(3):286-92. PubMed ID: 7921214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat.
    Ayalon D; Farhi Y; Comaru-Schally AM; Schally AV; Eckstein N; Vagman I; Limor R
    Neuroendocrinology; 1993 Aug; 58(2):153-9. PubMed ID: 8264861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Pinski J; Vadillo-Buenfil M; Groot K
    Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2398-402. PubMed ID: 8637885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiovulatory doses of antagonists of LH-RH inhibit LH and progesterone but not FSH and estradiol release.
    Kovács M; Koppán M; Mezö I; Teplán I; Flerkó B
    J Neuroendocrinol; 1993 Dec; 5(6):603-8. PubMed ID: 8680431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
    Bokser L; Srkalovic G; Szepeshazi K; Schally AV
    Neuroendocrinology; 1991 Aug; 54(2):136-45. PubMed ID: 1662786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.
    Bajusz S; Kovacs M; Gazdag M; Bokser L; Karashima T; Csernus VJ; Janaky T; Guoth J; Schally AV
    Proc Natl Acad Sci U S A; 1988 Mar; 85(5):1637-41. PubMed ID: 3278323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
    Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
    J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis).
    Weinbauer GF; Nieschlag E
    Andrologia; 1993; 25(3):141-7. PubMed ID: 8517553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75.
    Pinski J; Yano T; Miller G; Schally AV
    Prostate; 1992; 20(3):213-24. PubMed ID: 1533453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men.
    Behre HM; Böckers A; Schlingheider A; Nieschlag E
    Clin Endocrinol (Oxf); 1994 Feb; 40(2):241-8. PubMed ID: 8137524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH.
    Csernus VJ; Szende B; Groot K; Redding TW; Schally AV
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):111-8. PubMed ID: 2110458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
    Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV
    J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
    Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.
    Bajusz S; Csernus VJ; Janaky T; Bokser L; Fekete M; Schally AV
    Int J Pept Protein Res; 1988 Dec; 32(6):425-35. PubMed ID: 2469662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
    Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
    Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.